In full transparency, the following is a press release submitted to SOURCE media (photo courtesy)
HAMBURG, GERMANY – Evotec SE announced today, February 15, Cyprotex US, LLC, the US site of Cyprotex a wholly-owned subsidiary of Evotec, has completed its relocation from Watertown to a new state-of-the-art facility in Framingham, paving the way for significant further growth of its ADME-Tox services business for US-based customers.
Since the acquisition by Evotec in 2016, Cyprotex US, LLC, world leader in predictive toxicology and ADME research, has been growing its US business through partnerships with Pharma and biotech companies.
The relocation of the US site to 200 Staples Drive in Framingham goes along with upgrades to the latest liquid handling automation and mass spectrometry technology, translating to significant efficiency gains, higher capacity, and faster turnaround times and will mirror many of the assays offered at the Alderley Park, UK site of Cyprotex Discovery Ltd.
Further, Cyprotex’ customers and partners will stand to benefit from additional specialist services e.g. a full suite of transporter assays and a high-throughput transcriptomics offering for predicting drug-induced toxicity, which Cyprotex performs together with its parent company Evotec.
With 30,000 square feet, Cyprotex’ new facility at 200 Staples Drive provides a high-throughput alternative for its partners on their doorstep.
An opening event with clients will be held in April in Framingham.
Dr Craig Johnstone, Chief Operating Officer of Evotec, said “Integrating predictive toxicology and ADME research into the R&D continuum is a priority for the cost-efficient development of new medicines. Cyprotex’ expansion into a first-class scientific facility in Framingham will benefit both existing and new clients across the US. The co-location of Cyprotex’ offering in proximity to Evotec’s US East Coast sites, especially the sample management facility in Branford, CT, further allows us to drastically reduce turnaround times.”
Established in 1999, Cyprotex Limited was acquired by Evotec (www.evotec.com) in 2016. Cyprotex, an Evotec company, has sites at Alderley Park near Macclesfield, UK and in Framingham near Boston, USA. The company has dedicated and highly qualified employees with proven experience in a wide range of specialist techniques acquired across diverse industries. The majority of our clients focus in pharmaceutical research, however, we also support clients in the chemical, cosmetics and personal care, agrichemical and tobacco industries. Cyprotex specialises in in vitro and in silico ADME-Tox services. This includes in vitro ADME screening to support discovery projects, regulatory in vitro ADME and DDI studies during pre-clinical and clinical development, specialist mechanistic in vitro human and animal toxicity models (e.g. 3D models and MEA electrophysiology) and PBPK/QSAR modelling expertise.
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,500 highly qualified people. The Company’s 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.